Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

SANTA BARBARA, Calif., Jan. 9, 2023 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454...

Click to view original post